Matinas BioPharma (MTNB) Tops Q2 EPS by 1c

Matinas BioPharma (NYSE: MTNB) reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• Oman Warned European Allies Ship Fees Likely Needed For Hormuz - Bloomberg
• Synaptics (SYNA) call put ratio 1 call to 1.3 puts after On Semi (ON) acquiring in a $7B all-stock transaction
• Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print